8 апр. 2024 г. · ORBITA-COSMIC found no evidence that the CSR improved transmural myocardial perfusion, but the CSR did improve angina compared with placebo.

A double-blind, randomised, placebo-controlled trial of the coronary sinus Reducer in refractory angina: design and rationale of the ORBITA-COSMIC trial.

20 апр. 2024 г. · ORBITA-COSMIC found no evidence that the CSR improved transmural myocardial perfusion, but the CSR did improve angina compared with placebo.

8 апр. 2024 г. · A coronary sinus reducer (CSR) may lead to a significant reduction in the number of angina episodes in patients with chronic chest pain.

In a randomised, double-blinded trial in 2015, CSR improved angina compared to placebo. The therapeutic mechanism of the CSR is unknown. It is thought to ...

The ORBITA-COSMIC trial looks at a coronary sinus reducer in patients with refractory angina. This is an important study because these patients are highly ...

8 апр. 2024 г. · The small proof-of-concept ORBITA-COSMIC trial demonstrated that CSR implantation was associated with significant reduction in daily angina burden and heart ...

8 апр. 2024 г. · Al-Lamee pointed out that patients in ORBITA-COSMIC were extremely debilitated, with many of them reporting six angina episodes per day.

5 февр. 2024 г. · A double-blind, randomised, placebo-controlled trial of the coronary sinus Reducer in refractory angina: design and rationale of the ORBITA- ...

8 апр. 2024 г. · ACC.24 — Investigators, Dr Rasha K Al-Lamee and Dr Michael Foley (Imperial College London, UK) joined us to discuss the ORBITA COSMIC trial ...